Mast-Cell Sarcoma

A unifocal malignant tumor that consists of atypical pathological MAST CELLS without systemic involvement. It causes local destructive growth in organs other than in skin or bone marrow.

Also Known As:

Malignant Mastocytoma; Malignant Mastocytomas; Mast Cell Sarcoma; Mast-Cell Sarcomas; Mastocytomas, Malignant; Sarcoma, Mast Cell; Sarcomas, Mast-Cell; Mastocytoma, Malignant; Sarcoma, Mast-Cell

Networked: 15 relevant articles (0 outcomes, 1 trials/studies)

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
3.	Leukemia
4.	Mastocytosis
5.	Mast-Cell Leukemia (Leukemia, Mast Cell)

Experts

1.	Akin, Cem: 2 articles (04/2013 - 08/2003)
2.	Aldaoud, Ali: 1 article (01/2020)
3.	Behre, Gerhard: 1 article (01/2020)
4.	Fend, Falko: 1 article (01/2020)
5.	Franke, Georg-Nikolaus: 1 article (01/2020)
6.	Horny, Hans-Peter: 1 article (01/2020)
7.	Jentzsch, Madlen: 1 article (01/2020)
8.	Kubasch, Anne Sophie: 1 article (01/2020)
9.	Platzbecker, Uwe: 1 article (01/2020)
10.	Sabri, Osama: 1 article (01/2020)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Mast-Cell Sarcoma:

1.	Tryptases (Tryptase)IBA 01/01/2018 - "Histopathological, immunohistochemical, and flow cytometry studies of the resection specimens showed the tumor to be mostly composed of CD117-positive and mast cell tryptase-positive cells with features consistent with mast cell sarcoma. "
2.	Imatinib Mesylate (Gleevec)FDA Link 11/01/2011 - "Our results indicate that imatinib is of potential use in the treatment of mast cell sarcoma." 11/01/2011 - "Successful treatment of mast cell sarcoma of the uterus with imatinib." 04/01/2013 - "Molecular testing of mast cell sarcoma has not thus far detected the imatinib-resistant KIT D816V mutation, suggesting that recognition of these cases may facilitate specific targeted therapy." 11/01/2011 - "We report successful treatment of uterine mast cell sarcoma with imatinib in a 39-year-old woman who presented with abdominal distention and massive ascites. "
3.	Vitamin D3 24-HydroxylaseIBA 12/01/2017 - "In contrast to human skin, LAD2 mast cells cultured from a patient with mast cell sarcoma/leukaemia revealed that about 34% and 6.5% of the cells were immunopositive for VDR and CYP24A1, respectively. "
4.	Stem Cell FactorIBA 08/01/2003 - "Two novel stem cell factor (SCF) dependent human mast cell lines, designated LAD 1 and 2, were established from bone marrow aspirates from a patient with mast cell sarcoma/leukemia. " 08/01/2003 - "Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI."
5.	RadiumIBA 03/01/1994 - "The following total tumors (benign plus malignant) occurred in control dogs but not in radium dogs: brain = 3, peritoneum = 1, and pituitary = 4. Malignant tumors other than leukemia appearing in control animals and not among radium dogs were brain = 2, lymph nodes = 1, adrenal = 3, uterus = 1, and pancreas = 5. Tumors that occurred in dogs given radium and not in controls were 3 mast cell sarcomas and 2 tumors of the thymus (1 malignant). "
6.	InterferonsIBA 02/01/2003 - "Despite interferon therapy, a mast-cell sarcoma of the sternum developed 1 year after symptom onset, followed 1 year later by acute myeloblastic leukemia, which was rapidly fatal."
7.	Cortisone FDA Link 11/01/1953 - "Preliminary observations on the use of cortisone in canine mast cell sarcoma."
8.	octanoic acid (caprylic acid)IBA 09/02/1975 - "The membrane mobility agent 2-(2-methoxyethoxy)-ethyl 8-cis-2-n-octyl-cyclopropyl)-octanoate promotes cap formation from wheat germ agglutinin-receptor combinations at the expense of agglutination in membranes of malignant mastocytoma cells."
9.	wheat germ agglutinin receptorIBA 09/02/1975 - "The membrane mobility agent 2-(2-methoxyethoxy)-ethyl 8-cis-2-n-octyl-cyclopropyl)-octanoate promotes cap formation from wheat germ agglutinin-receptor combinations at the expense of agglutination in membranes of malignant mastocytoma cells."

Therapies and Procedures

1.	Therapeutics 12/01/2019 - "Next-Generation Sequencing Directs Therapy and Delineates a Clonal Relationship in Mast Cell Sarcoma and Acute Myeloid Leukemia." 01/01/2018 - "Rare variants - including mast cell leukemia, aggressive mastocytosis, and the exceedingly rare mast cell sarcoma - require cytoreductive therapy. " 04/01/2013 - "Molecular testing of mast cell sarcoma has not thus far detected the imatinib-resistant KIT D816V mutation, suggesting that recognition of these cases may facilitate specific targeted therapy." 02/01/2003 - "Despite interferon therapy, a mast-cell sarcoma of the sternum developed 1 year after symptom onset, followed 1 year later by acute myeloblastic leukemia, which was rapidly fatal."
2.	Hematopoietic Stem Cell Transplantation 01/01/2020 - "Allogeneic Hematopoietic Stem Cell Transplantation in a Rare Case of Tonsillar Mast Cell Sarcoma."
3.	Radiotherapy 12/15/1988 - "A large infiltrating mast cell sarcoma in a dog, which had been refractory before surgical excision, was controlled 2 months after completion of a combined radiotherapy and hyperthermia regimen. " 12/15/1988 - "Use of hyperthermia and radiotherapy in treatment of a large mast cell sarcoma in a dog."
4.	Combination Drug Therapy (Combination Chemotherapy) 02/01/2001 - "Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy." 02/01/2001 - "Systemic combination chemotherapy led to marked transient tumor regression in this proliferating mast cell sarcoma in an unusual intracranial location."
5.	Drug Therapy (Chemotherapy) 04/01/1989 - "Lymphoid leucaemia in a dog after chemotherapy for mast cell sarcomas."